Cancer Moonshot program for specific cancer types
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This study is for people with certain cancers: lung, breast, gastric (stomach), pancreatic, or ovarian. It aims to test a Moonshot-style approach to improve cancer care for these groups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: lung, breast, gastric (stomach), pancreatic, or ovarian
- You must not have any other cancer type besides the study’s listed cancers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immunotherapy for people with advanced cancer that has not responded to standard treatments. It aims to see if this personalized approach is safe and effective.
This trial tests an antibody treatment for people with stage IV cancer that has not responded to previous treatment. It aims to find a new option for patients with several types of advanced solid tumors.
This Phase 1/2 trial tests a combination treatment for advanced or metastatic stomach and food-pipe (gastroesophageal junction) cancer: a chemotherapy regimen (CapeOX) plus the immunotherapy drug sintilimab and the targeted drug bevacizumab. It aims to see how well this combination controls the cancer and how safely it can be given.
This study uses advanced testing (molecular profiling and imaging) to better understand cancers and help guide treatment. It is for people with certain advanced cancers who have not yet had immunotherapy or targeted therapy.
This trial tests a combination of chemotherapy (conversion therapy), surgery, and radiation for people with stomach cancer that has spread only to lymph nodes behind the stomach. The goal is to see if this approach can help shrink the cancer and improve outcomes.
This trial tests a new combination of drugs (osemitamab, pembrolizumab, and chemotherapy) as a first treatment for people with advanced or metastatic stomach or gastroesophageal junction cancer. It's looking for patients whose tumors have a specific protein called CLDN18.2, and who have not had prior treatment for advanced disease.
Hear when a new Malignant Neoplasm of Body of Stomach in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.